Achillion pharmaceuticals inc (ACHN)
Income statement / Quarterly
Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Sep'10Jun'10
Revenue

-

0

0

-

-

0

0

-

0

0

0

15,000

0

0

0

31,591

33,820

711

0

-

-

-

0

-

0

0

0

118

0

0

2,489

62

64

56

65

170

187

Operating expenses
Research and development

14,993

15,932

14,817

12,204

12,842

11,023

14,049

14,239

15,620

18,253

15,495

12,710

16,701

14,154

13,278

9,642

11,983

19,772

15,156

16,426

12,070

12,177

12,842

10,107

11,342

16,568

8,719

8,437

12,641

8,979

8,942

9,937

8,615

8,896

7,993

5,657

4,814

General and administrative

6,061

5,109

5,157

5,970

4,447

7,463

6,016

10,115

4,843

5,363

5,648

7,579

4,848

5,155

5,440

5,450

4,856

10,127

4,243

5,235

3,694

3,589

3,393

3,388

2,734

3,545

3,074

2,935

2,647

2,580

2,739

2,572

1,922

2,436

2,223

1,690

1,690

Restructuring charges (Note 4)

0

0

655

0

75

75

1,750

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total operating expenses

21,054

21,041

20,629

18,174

17,364

18,561

21,815

24,354

20,463

23,616

21,143

20,289

21,549

19,309

18,718

15,092

16,839

29,899

19,399

21,661

15,764

15,766

16,235

13,495

14,076

20,113

11,793

11,372

15,288

11,559

11,681

12,509

10,537

11,332

10,216

7,347

6,504

Loss from operations

-21,054

-21,041

-20,629

-18,174

-17,364

-18,561

-21,815

-24,354

-20,463

-23,616

-21,143

-5,289

-21,549

-19,309

-18,718

16,499

16,981

-29,188

-19,399

-21,661

-15,764

-15,766

-16,235

-13,495

-14,076

-20,113

-11,793

-11,254

-15,288

-11,559

-9,192

-12,447

-10,473

-11,276

-10,151

-7,177

-6,317

Other income (expense)
Interest income

1,473

1,621

1,681

1,585

1,484

1,370

1,239

1,164

1,133

1,085

1,008

874

846

828

679

465

346

225

152

79

101

117

158

154

166

185

77

-

-

-

-

-

-

-

40

27

15

Interest income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

49

55

65

-

44

30

-

-

-

Interest expense

2

6

11

12

4

8

12

13

8

12

17

14

27

12

15

12

12

15

16

14

4

8

11

9

9

12

22

15

16

23

14

10

9

4

22

67

82

Other income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

8,944

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-19,583

-19,426

-18,959

-16,601

-15,884

-17,199

-20,588

-23,203

-19,338

-22,543

-20,152

-4,429

-20,730

-18,493

-18,054

16,952

26,259

-28,978

-19,263

-21,596

-15,667

-15,657

-16,088

-13,350

-13,919

-19,940

-11,738

-11,204

-15,255

-11,527

-9,141

-12,385

-10,438

-11,250

-10,133

-7,217

-6,384

Basic and diluted net loss per share (Note 5)

-0.14

-0.14

-0.14

-0.12

-0.12

-0.12

-0.15

-0.17

-0.14

-0.16

-0.15

-0.03

-0.15

-0.14

-0.13

-

-

-0.25

-0.17

-

-

-0.16

-0.17

-0.14

-0.14

-0.21

-0.14

-0.15

-0.20

-0.16

-0.13

-0.18

-0.15

-0.19

-0.17

-0.15

-0.17

Total comprehensive loss (Note 9)

-19,653

-19,254

-18,639

-16,592

-15,673

-16,933

-20,884

-23,529

-19,281

-22,680

-20,286

-4,588

-20,731

-18,447

-17,744

16,981

26,217

-29,058

-19,203

-21,601

-15,699

-15,656

-16,070

-13,352

-13,769

-20,051

-11,788

-11,230

-15,222

-11,543

-9,093

-12,362

-10,485

-11,246

-10,135

-

-

Weighted average number of shares used in computing basic and diluted net loss per share

139,589

138,761

138,716

138,646

138,586

138,426

138,014

137,887

137,375

136,736

136,722

136,667

136,681

136,680

136,640

-

-

117,770

111,202

-

-

97,017

96,792

96,854

96,648

96,580

85,850

79,591

74,647

71,211

70,411

-

69,725

58,938

-

-

-

Basic net income (loss) per share (Note 5)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.19

-

-

-

-0.16

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Diluted net income (loss) per share (Note 5)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.19

-

-

-

-0.16

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Basic weighted average shares outstanding

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

136,439

-

-

-

99,031

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Diluted weighted average shares outstanding

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

140,024

-

-

-

99,031

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Weighted average shares used in computing basic and diluted net loss per share attributable to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

47,576

38,540